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CASE REPORTMethotrexate-induced CD301 T-cell
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For more than 30 years, methotrexate (MTX) has
been a mainstay in the treatment of various
inflammatory disorders including rheumatoid
arthritis (RA) and psoriasis.1 Off-label use of MTX
has expanded in recent years, as it is found to be
effective in treating dermatoses such as atopic
dermatitis, bullous pemphigoid, pemphigus
vulgaris, and mycosis fungoides.1 Because of its
common use in dermatology, the oncogenic
potential of MTX is of special significance for the
clinician interested in prescribing this drug.1
Although MTX has been implicated in squamous
cell carcinoma in patients treated for psoriasis, its
potential to induce lymphoma is controversial, as
studies find either an increase or no clinically
significant increase in malignant potential with
chronic MTX use.1 Herein, we report a case of a
CD301 T-cell lymphoproliferative disorder (LPD) of
the lip and oral cavity in a patient taking MTX for RA.
CASE REPORT
A 66-year-old white woman with a 20-year history
of RA presented to our dermatology clinic with a
10-month history of a painful lesion on her lower lip.
She was initially treated with topical desoximetasone
and triamcinolone until July 2013 when it was
discontinued because of treatment failure. Topical
clobetasol ointment was then initiated and provided
the patient some relief until she reported a burning
sensation after administration. At the time of
presentation in October 2013, the lip lesion had
progressed to a deep ulceration of the lip, and she
reported that the lesion spread onto her upper lip
and the floor of her mouth, impeding her ability tothe Departments of Dermatologya and Pathology,b Medical
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wang@ucdavis.edu.eat and causing significant weight loss. Our patient
had been taking MTX for RA for greater than 5 years.
Clinical examination of the vermillion border of
the lower lip found a large, erythematous, atrophic
area surrounded by soft nodules that extended to the
mucosal surface of the lower lip (Fig 1, A). The right
upper lip had a 1-cm atrophic defect without
erosions or ulcerations. The anterior portion of the
floor of her mouth was nodular and erythematous.
No lymphadenopathy or hepatosplenomegaly was
appreciated.
A 5-mm shave biopsy specimen from the lower lip
was taken for pathologic examination. A small
portion of the oral mucosa was ulcerated and
infiltrated by an atypical mononuclear cell infiltrate
(Fig 1, B). The epidermis was free of atypia and
lacked viral cytopathic changes.
Immunoperoxidase stains found that the atypical
infiltrate was negative for CD20, PAX-5, and CD79a,
ruling out a B-cell lineage. Although the atypical cells
were CD3-, CD4-, and CD7-, they were CD21, CD51,
and CD81, suggestive of a T-cell lineage. Strong
CD30 expression was found, whereas ALK-1 staining
was negative (Fig 1, C ). These immunohisto-
chemical studies suggested a histologic diagnosis of
CD301 ALK-1- T-cell LPD with involvement of the
oral mucosa. Other lymphomas, specificallyJAAD Case Reports 2016;2:354-6.
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Fig 1. MTX-induced CD301 LPD. A, Region of lower lip ulceration. B, Hematoxylin-eosin
stain. C, Strong CD301 stain of the malignant cell population. D, EBER1 staining of the
malignant cells.
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not considered after a negative bone marrow biopsy
result and a positron emission tomography scan that
showed bandlike focal fluorodeoxyglucose uptake
in the soft tissues anterior to the mandible without
other evidence of lymphoma. Subsequent Epstein-
Barreencoded RNA (EBER) staining of the histologic
specimen, however, showed abundant positive cells
in small-, medium-, and large-sized lymphocytes.
This finding suggested that her LPD was associated
with Epstein-Barr virus (EBV) infection (Fig 1, D).
Based on the positive EBER studies and the patient’s
history of MTX use, the case was reclassified as an
immunodeficiency-related CD301 T-cell LPD. We
discontinued MTX and initiated conservative treat-
ment with twice daily clobetasol ointment. Within
2months of treatment, the patient reported complete
resolution of the lip lesions and denied any new
or changing lesions, suggesting her lesion was
related to MTX use. At 1-year follow-up, the patient
remained disease free.
DISCUSSION
The World Health Organization in 2008 defined
a broad category of ‘‘posttransplantation and
iatrogenic’’ LPDs that recognizes iatrogenic immu-
nosuppression as a pathogenic factor, with MTXincluded as an etiologic agent of iatrogenic
immunodeficiency-associated LPDs.2-4 The pro-
posed mechanism by which this occurs is via
MTX-induced suppression of EBV-specific cytotoxic
T cells, which promotes the reactivation of
EBV-specific B cells that proliferate.4 Although
MTX-induced LPDs in RA patients have been
discussed in previous case reports, lesions
presenting on the skin and oral cavity were rarely
reported in the literature.5,6 Furthermore, a literature
search found that most EBV-related cases have B-cell
involvement, unlike the T-cell involvement seen in
our patient.7 We report a rare case of a MTX-induced
CD301 T-cell LPD presenting with an isolated
primary lesion on the lip.
Our case highlights the importance of clinical-
pathologic correlation with regard to challenging
diagnoses. With larger numbers of patients on
immunosuppressive therapies, a greater awareness
of immunosuppression-related LPDs is necessary for
early diagnosis and treatment. Despite a location
similar to the B-cell LPD described by Jaffe et al3 on
the lip, our tumor showed clear features of a T-cell
LPD despite the absence of CD3. Additional use of
EBER testing because of known immunosuppressant
use helped us arrive at the correct diagnosis, namely,
a LPD related to immunosuppression. Thus, EBER
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in patients presenting with unusual cutaneous find-
ings in the context of iatrogenic immunosuppression
with MTX or other immunosuppressive agents.
Finally, this case shows that it is increasingly
important that relevant clinical information is
provided to the pathologist upon submission of a
tissue specimen to help determine which immuno-
histologic tests are applied to the biopsy specimen.
In many cases of lymphoproliferative conditions
induced by iatrogenic immunosuppression, resolu-
tion of the tumor occurs with withdrawal of the
medication.6-9 It is not clear that topical steroids were
necessary in our patient, but we did observe rapid
and complete resolution of the tumor after
withdrawal of MTX and use of topical clobetasol. It
is critical for dermatologists to monitor patients
closely for any new or unusual mucocutaneous
lesions in patients taking MTX and to consider MTX
as a risk factor for any new neoplastic processes.
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